- Home
- FULC
as 11-22-2024 4:00pm EST
Fulcrum Therapeutics Inc is a clinical-stage biopharmaceutical company. The company's programs in clinical development are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy (FSHD) and FTX-6058, a small molecule designed to increase expression of fetal hemoglobin for the treatment of sickle cell disease and other hemoglobinopathies, including beta-thalassemia.
| Founded: | 2015 | Country: | United States |
| Employees: | N/A | City: | CAMBRIDGE |
| Market Cap: | 221.5M | IPO Year: | 2019 |
| Target Price: | $7.44 | AVG Volume (30 days): | 843.4K |
| Analyst Decision: | Hold | Number of Analysts: | 10 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.29 | EPS Growth: | N/A |
| 52 Week Low/High: | $2.86 - $13.70 | Next Earning Date: | 11-13-2024 |
| Revenue: | $80,871,000 | Revenue Growth: | 2987.86% |
| Revenue Growth (this year): | 2821.96% | Revenue Growth (next year): | N/A |
Latest Fulcrum Therapeutics Inc. News
FULC Breaking Stock News: Dive into FULC Ticker-Specific Updates for Smart Investing
Simply Wall St.
10 days ago
Fulcrum Therapeutics Third Quarter 2024 Earnings: US$0.35 loss per share (vs US$0.39 loss in 3Q 2023)
GuruFocus.com
11 days ago
Fulcrum Therapeutics Inc (FULC) Q3 2024 Earnings Call Highlights: Strategic Advancements Amidst ...
GlobeNewswire
12 days ago
Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Third Quarter 2024
GlobeNewswire
12 days ago
Fulcrum Therapeutics to Participate in the Stifel Healthcare Conference
GlobeNewswire
19 days ago
Fulcrum Therapeutics to Host Third Quarter 2024 Financial Results Conference Call and Webcast on Wednesday, November 13, 2024 at 8:00 a.m. ET
Zacks
a month ago
Fulcrum Before Q3 Earnings: How Should Investors Play the Stock?
Simply Wall St.
a month ago
We're Interested To See How Fulcrum Therapeutics (NASDAQ:FULC) Uses Its Cash Hoard To Grow
Investor's Business Daily
a month ago
Avidity Biosciences, Up 441%, Nears Another Record High As Dystrophy Space Heats Up
Compare FULC vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "FULC Fulcrum Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.